AKTX Akari Therapeutics Plc - Americ

6.61
-0.08  -1%
Previous Close 6.69
Open 6.86
Price To book 2.31
Market Cap 77.84M
Shares 11,776,000
Volume 26,350
Short Ratio 2.88
Av. Daily Volume 735,647

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 interim data released April 24, 2017. Phase 3 program to commence 4Q 2017 with initial data due 1Q 2019.
Coversin
Paroxysmal nocturnal hemoglobinuria (PNH)

Latest News

  1. INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Akari Therapeutics, Plc and Encourages Investors with Losses to Contact the Firm
  2. SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Akari Therapeutics Plc (AKTX) & Lead Plaintiff Deadline: July 11, 2017  
  3. SHAREHOLDER ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Akari Therapeutics, Plc and Encourages Investors with Losses to Contact the Firm
  4. INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in Akari Therapeutics, Plc to Contact Brower Piven before the Lead Plaintiff Deadline in Class Action Lawsuit
  5. AKTX LOSS NOTICE: Rosen Law Firm Reminds Akari Therapeutics, Plc Investors of Important Deadline in Class Action - AKTX
  6. Investor Alert: Kaplan Fox Announces Investigation Of Akari Therapeutics, PLC
  7. AKARI THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akari Therapeutics, Plc
  8. IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Akari Therapeutics, Plc and Encourages Investors with Losses to Contact the Firm
  9. AKARI LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Akari Therapeutics, Plc To Contact The Firm
  10. Amgen Evenity Approval Derailed on Cardiovascular Side Effect
  11. IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Akari Therapeutics, Plc and Encourages Investors with Losses to Contact the Firm
  12. AKARI THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akari Therapeutics, Plc - (AKTX)
  13. IMPORTANT INVESTOR ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against Akari Therapeutics, Plc and Encourages Investors with Losses to Contact the Firm
  14. SHAREHOLDER ALERT:  Pomerantz Law Firm Announces the Filing of a Class Action against Akari Therapeutics plc and Certain Officers – AKTX
  15. IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Akari Therapeutics, Plc and Encourages Investors with Losses to Contact the Firm
  16. What Falling Estimates & Price Mean for AveXis, Inc. (AVXS)
  17. BioDelivery Sciences International (BDSI) Jumps: Stock Up 5%
  18. AKARI THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit against Akari Therapeutics, Plc
  19. Why Is Vertex Pharma (VRTX) Stock Soaring This Year?